US Broker Ratings

Disc Medicine, Inc. (IRON) Investor Outlook: Unveiling a 51% Potential Upside in the Biotech Sector

Disc Medicine, Inc. (NASDAQ: IRON), a promising name in the biotechnology sector, is capturing investor attention with its substantial 51.37% potential upside. This clinical-stage biopharmaceutical company, with a market cap..

Centessa Pharmaceuticals (CNTA) Stock Analysis: Exploring a 57% Potential Upside for Investors

Investors with a keen eye on the biotechnology sector might find Centessa Pharmaceuticals plc (NASDAQ: CNTA) an intriguing proposition. With a substantial market capitalization of $3.72 billion, Centessa is a..

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Navigating a 20% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (NASDAQ: LMAT), a key player in the healthcare sector specializing in medical instruments and supplies, is drawing investor attention with its promising growth prospects. Headquartered in Burlington,..

Premier, Inc. (PINC) Stock Analysis: Navigating a Flat Landscape with 2.97% Dividend Yield

Premier, Inc. (NASDAQ: PINC), a key player in the healthcare sector, operates primarily in the health information services industry. With a market cap of $2.34 billion, this Charlotte, North Carolina-based..

SS Innovations International (SSII) Stock Analysis: Exploring the 192.50% Revenue Growth in the Healthcare Sector

SS Innovations International, Inc. (SSII), a key player in the medical devices industry, is making waves with its substantial 192.50% revenue growth. Headquartered in Gurugram, India, this healthcare company is..

Galapagos NV (GLPG) Stock Analysis: A High-Stakes Bet in Biotechnology with an 18.9% Revenue Growth

Galapagos NV (GLPG), a Belgian biotechnology powerhouse, is an intriguing player in the healthcare sector. With a market capitalization of $2.26 billion, Galapagos continues to draw attention in the biotechnology..

ImmunityBio, Inc. (IBRX) Stock Analysis: Exploring a Potential 92.5% Upside

Investors with an eye on the biotechnology sector may find ImmunityBio, Inc. (NASDAQ: IBRX) an intriguing prospect. With its current market cap standing at $6.04 billion and a robust pipeline..

IDEAYA Biosciences (IDYA): Unpacking the 46.63% Potential Upside in Precision Oncology

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is gaining notable attention in the biotechnology sector, offering a promising proposition for investors keen on the precision oncology market. With its strategic focus on..

Certara, Inc. (CERT) Investor Outlook: Evaluating a 49% Potential Upside in Health Information Services

Certara, Inc. (NASDAQ: CERT) is drawing attention in the healthcare sector, particularly in the health information services industry, where it operates as a key player providing technology-enabled solutions for biosimulation...

PROCEPT BioRobotics (PRCT) Stock Analysis: A 74% Potential Upside in the Medical Robotics Field

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is making waves in the healthcare sector, specifically within the medical devices industry. The company’s focus on developing transformative solutions in urology has captured the..

Enovis Corporation (ENOV) Stock Analysis: A 103% Upside Potential in the Healthcare Sector

Enovis Corporation (ENOV), a prominent player in the healthcare sector specializing in medical devices, has caught the attention of investors with its compelling growth prospects and substantial upside potential. With..

Amicus Therapeutics, Inc. (FOLD): Investor Outlook with a Focus on Growth and Revenue Potential

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is a noteworthy player in the biotechnology sector, focusing on the development and commercialization of treatments for rare diseases. With a market capitalization of $4.48..

BGM Group Ltd. (BGM) Stock Analysis: Navigating Challenges in the Chinese Healthcare Sector

BGM Group Ltd. (BGM), a burgeoning player in the Chinese healthcare sector, offers an intriguing opportunity for investors with a penchant for high-risk, high-reward scenarios. Specializing in the manufacture and..

Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis: 23% Potential Upside in the Healthcare Sector

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) is making waves in the healthcare sector with its promising portfolio of biopharmaceutical innovations targeted at cardiovascular and inflammatory diseases. With a market capitalization..

NovoCure Limited (NVCR) Stock Analysis: Is the 97% Potential Upside a Game Changer for Investors?

NovoCure Limited (NASDAQ: NVCR), a notable name in the medical devices sector, is capturing investor interest with a striking potential upside of 97.47%, according to analyst ratings. Based in Baar,..

Apellis Pharmaceuticals, Inc. (APLS) Stock Report: Exploring the 48.7% Potential Upside and Analyst Consensus

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stands out in the biotechnology sector with a unique focus on developing solutions for diseases with high unmet medical needs. With a market capitalization of..

Alvotech (ALVO) Growth Potential: A Deep Dive into Its 316.67% Upside and Biosimilar Innovations

Alvotech (NASDAQ: ALVO), a Luxembourg-based biopharmaceutical company, is capturing investor attention with its focus on developing and manufacturing biosimilar medicines. The company operates within the Healthcare sector, specifically in the..

Denali Therapeutics Inc. (DNLI): Investor Outlook Reveals 44.49% Potential Upside in Neurodegenerative Drug Development

Denali Therapeutics Inc. (NASDAQ: DNLI), a trailblazer in the biotechnology sector, is capturing the attention of investors with its focus on developing therapeutics for neurodegenerative and lysosomal storage diseases. As..

Perrigo Company plc (PRGO) Investor Outlook: Navigating a 46.65% Potential Upside in the Healthcare Sector

Perrigo Company plc (NASDAQ: PRGO) is a prominent player in the healthcare sector, specializing in the manufacture of over-the-counter health and wellness products. Headquartered in Dublin, Ireland, Perrigo operates through..

Kymera Therapeutics (KYMR): A Biotech Stock with 54% Potential Upside Amid Innovative Protein Degradation Focus

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is rapidly capturing investor attention in the biotechnology sector with its innovative approach to drug development and a robust pipeline. Specializing in the discovery and..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds